This brief identifies time-bound PEPFAR authorities and also provides a detailed side-by-side comparison of PEPFAR’s authorizing legislation over time.
- view as grid
- view as list
How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?
The brief provides a quick explainer of the prescription drug provisions in the Inflation Reduction Act signed into law on August 16, 2022 and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
With federal agencies preparing to update parity regulations and Congress considering reforms, our new report explains existing parity requirements, including who they apply to and how their enforced, and highlights key policy issues raised by regulators and advocates that could be addressed in the future. Those issues include: Simplifying parity standards…
This brief discusses federal mental health parity protections — what they are, who they apply to, who enforces them and key policy issues as Congress and federal agencies evaluate improvements to the law to address gaps in mental health coverage and access.
Fate of Medicaid Expansion and Filling the Coverage Gap May Once Again Depend on the Outcome of State Elections
This post examines the potential for this year’s midterm elections to decide the fate of Medicaid expansion, with gubernatorial races in 10 of the 12 states that have not expanded, including Georgia, Kansas and Wisconsin, where the gubernatorial race is considered a toss-up. South Dakota voters also will decide a Medicaid expansion ballot initiative.
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans.
Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times guest essay, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
This policy watch examines early data showing that Black and Hispanic people are bearing a disproportionate burden of monkeypox cases and discusses the importance of centering equity in response efforts, including prevention, testing, and treatment.
Five Things to Know about the Renewal of Extra Affordable Care Act Subsidies in the Inflation Reduction Act
As part of the Inflation Reduction Act, the Senate recently passed a three-year extension (through 2025) of enhanced subsidies for people buying their own health coverage on the Affordable Care Act Marketplaces. The enhanced subsidies increase the amount of financial help available to those already eligible and also newly expand subsidies to middle-income people, many of whom were previously priced out of coverage. Here’s what to know about the likely renewal of these subsidies:
The Inflation Reduction Act includes several landmark health care provisions that would lower prescription drug costs for people with Medicare, reduce Medicare drug spending and extend enhanced subsidies for Affordable Care Act marketplace coverage. On Thursday, August 11, a panel of KFF experts held a web briefing to explain these…